Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
or

Springworks Therapeutics Inc (SWTX)

Springworks Therapeutics Inc (SWTX)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
41.88 -2.25 (-5.10%) 04/01/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 41.63 -0.25 (-0.60%) 19:51 ET
Quote Overview for Tue, Apr 1st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
40.98
Day High
44.18
Open 43.94
Previous Close 44.13 44.13
Volume 2,586,000 2,586,000
Avg Vol 2,023,045 2,023,045
Stochastic %K 12.10% 12.10%
Weighted Alpha -21.45 -21.45
5-Day Change -5.33 (-11.29%) -5.33 (-11.29%)
52-Week Range 28.21 - 62.00 28.21 - 62.00
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,306,925
  • Shares Outstanding, K 74,936
  • Annual Sales, $ 191,590 K
  • Annual Income, $ -258,130 K
  • EBIT $ -278 M
  • EBITDA $ -275 M
  • 60-Month Beta 0.75
  • Price/Sales 18.54
  • Price/Cash Flow N/A
  • Price/Book 7.33

Options Overview Details

View History
  • Implied Volatility 123.63% ( +2.46%)
  • Historical Volatility 57.03%
  • IV Percentile 86%
  • IV Rank 63.00%
  • IV High 169.36% on 01/10/25
  • IV Low 45.76% on 09/03/24
  • Put/Call Vol Ratio 0.61
  • Today's Volume 13,394
  • Volume Avg (30-Day) 15,772
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 135,878
  • Open Int (30-Day) 138,511

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.79
  • Number of Estimates 6
  • High Estimate -0.65
  • Low Estimate -0.93
  • Prior Year -1.18
  • Growth Rate Est. (year over year) +33.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.98 +2.20%
on 04/01/25
Period Open: 57.76
56.90 -26.40%
on 03/03/25
-15.88 (-27.49%)
since 02/28/25
3-Month
31.95 +31.06%
on 01/15/25
Period Open: 36.13
62.00 -32.45%
on 02/20/25
+5.75 (+15.91%)
since 12/31/24
52-Week
28.21 +48.46%
on 10/24/24
Period Open: 47.62
62.00 -32.45%
on 02/20/25
-5.74 (-12.05%)
since 04/01/24

Most Recent Stories

More News
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week

Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025.

TNYA : 0.5440 (-4.58%)
CSCI : 2.87 (+1.77%)
MLYS : 13.84 (-12.85%)
SWTX : 41.88 (-5.10%)
MGX : 1.3200 (-2.94%)
SpringWorks Therapeutics Leads Biotech Pack In Weekly Retail Follower Surge: What's Fueling Interest?

Investor attention is now on whether Merck will confirm a formal offer as speculation over a potential acquisition continues dominating discussions around the stock.

VTI : 275.77 (+0.34%)
XBI : 78.16 (-3.63%)
IWM : 199.51 (+0.01%)
SWTX : 41.88 (-5.10%)
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

SWTX : 41.88 (-5.10%)
SpringWorks Therapeutics Gains Retail Interest Ahead Of Q4 Earnings – What Investors Expect

Recent investor enthusiasm has been fueled by reports that German healthcare giant Merck KGaA is in advanced talks to acquire SpringWorks.

VTI : 275.77 (+0.34%)
XBI : 78.16 (-3.63%)
IWM : 199.51 (+0.01%)
SWTX : 41.88 (-5.10%)
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLIâ„¢ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN 

SWTX : 41.88 (-5.10%)
SpringWorks Therapeutics Announces FDA Approval of GOMEKLIâ„¢ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN 

SWTX : 41.88 (-5.10%)
Springworks Stock Soars To Nearly 3-Year High On Buyout Buzz, Retail Sentiment Rockets

Reuters reported that German healthcare and technology group Merck KGaA is in advanced talks to acquire the company.

VTI : 275.77 (+0.34%)
XBI : 78.16 (-3.63%)
IWM : 199.51 (+0.01%)
SWTX : 41.88 (-5.10%)
SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025

SWTX : 41.88 (-5.10%)
SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down

SpringWorks Therapeutics SWTX announced preliminary net product revenues for fourth-quarter and full-year 2024 for its sole marketed drug, Ogsiveo (nirogacestat). The drug is approved for treating adult...

CTMX : 0.5800 (-8.78%)
VYGR : 3.37 (-0.30%)
CSTL : 19.78 (-1.20%)
SWTX : 41.88 (-5.10%)
SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference

SWTX : 41.88 (-5.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

SpringWorks Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing life-changing medicines for patients with severe rare diseases and cancer. The company's product pipeline consists of Nirogacestat and Mirdametinib which are in clinical stage. SpringWorks Therapeutics...

See More

Key Turning Points

3rd Resistance Point 46.91
2nd Resistance Point 45.55
1st Resistance Point 43.71
Last Price 41.88
1st Support Level 40.51
2nd Support Level 39.15
3rd Support Level 37.31

See More

52-Week High 62.00
Fibonacci 61.8% 49.09
Fibonacci 50% 45.10
Last Price 41.88
Fibonacci 38.2% 41.12
52-Week Low 28.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies